Effectiveness of pioglitanone hydrochloride on cerebral vasospasm after subarachnoid hemorrhage (SAH)

Effectiveness of pioglitanone hydrochloride on cerebral vasospasm after subarachnoid hemorrhage (SAH) - Effect of pioglitazone on vasospasm after SAH

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002768

Enrollment

200

Registered

2009-12-01

Start date

2008-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subarachnoid hemorrhage

Interventions

administration of pioglitazone administration of placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient who was admitted with subarachnoid hemorrhage, blood sugar over 80 mg/dl at any time.

Exclusion criteria

Exclusion criteria: old person over 90 year-old, medicine hypersensitivity patient, pregnant woman or woman who has pregnancy possibly, hypoglycemia, person who was judged inadequat as patient by doctor.

Design outcomes

Primary

Measure	Time frame
functional prognosis (modified-Ranking Scale), evaluation of vasospasm by angiography, evaluation of cerebral infarction by CT or MRI	—

Secondary

Measure	Time frame
evaluation of adverse reaction	—

Countries

Japan

Contacts

Public ContactShiegru Tani

Tokyo Womens Medical University Medical Center East Department of Neurosurgery

stanine@dnh.twmu.ac.jp03-3810-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026